68Ga与177Lu标记整合素αvβ6靶向放射诊疗肽的临床前评价
本研究开发了靶向整合素αvβ6的肽DOTA-5G(1)及白蛋白结合修饰版DOTA-albumin-binding moiety-5G(2),分别用68Ga标记用于PET/CT显像、177Lu标记用于治疗。临床前结果显示两种肽对αvβ6高亲和力(<55 nM),177Lu-2因引入白蛋白结合基团使肿瘤摄取和滞留较177Lu-1增加5倍,剂量限制器官为肾脏,治疗使中位生存期较对照组延长1.5至2倍,人体剂量学数据提示177Lu-2有治疗胰腺导管腺癌的潜力。
要点
- 肽1和肽2对αvβ6的亲和力<55 nM,68Ga-1、68Ga-2、177Lu-1和177Lu-2均以高放射化学纯度合成。
- 177Lu-2引入白蛋白结合基团后,肿瘤摄取和滞留较177Lu-1随时间增加5倍。
- 基于扩展剂量学数据,177Lu-2的剂量限制器官为肾脏;治疗使中位生存期较对照组延长1.5至2倍。
核心结论
- 68Ga-1和177Lu-2在体外和体内均对整合素αvβ6显示高亲和力,可快速内化进入BxPC-3细胞,并在小鼠和人血清中稳定。
- 两种放射性示踪剂在临床前研究中表现出良好的药代动力学,主要经肾脏排泄,肿瘤与正常组织比值良好。
- 有利的人体剂量学数据提示177Lu-2有作为胰腺导管腺癌治疗手段的潜力。
研究设计与样本
- 在固相上合成肽1和肽2,用酶联免疫吸附试验评估其对αvβ6的亲和力。
- 用68Ga和177Lu对肽进行放射性标记,在αvβ6阳性BxPC-3人胰腺癌细胞中评估68Ga-1和177Lu-2的体外细胞结合、内化和外排。
- 在荷皮下BxPC-3肿瘤的雌性nu/nu小鼠上进行68Ga-1和68Ga-2的PET/CT显像。
- 对68Ga-1(注射后1和2小时)、68Ga-2(注射后2和4小时)及177Lu-1和177Lu-2(注射后1、24、48和72小时)进行生物分布研究。
- 使用OLINDA/EXM 1.1将177Lu-2生物分布数据外推估算人体剂量学数据,并在荷BxPC-3肿瘤小鼠中评估177Lu-2的治疗效果。
主要发现
- 肽1和肽2通过酶联免疫吸附试验对αvβ6显示高亲和力(<55 nM)。
- 68Ga-1、68Ga-2、177Lu-1和177Lu-2以高放射化学纯度合成。
- 在BxPC-3细胞中观察到68Ga-1和177Lu-2的快速体外结合和内化。
- PET/CT显像和生物分布研究显示BxPC-3肿瘤中有摄取。
- 177Lu-2中引入白蛋白结合基团使肿瘤摄取和滞留随时间较177Lu-1增加5倍。
关键数值与推荐
- 肽1和肽2对αvβ6的亲和力<55 nM(酶联免疫吸附试验)。
- 177Lu-2引入白蛋白结合基团后肿瘤摄取和滞留较177Lu-1增加5倍。
- 基于扩展剂量学数据,177Lu-2的剂量限制器官为肾脏。
- 177Lu-2治疗使中位生存期较对照组延长1.5至2倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The integrin αvβ6, an epithelium-specific cell surface receptor, is overexpressed on numerous malignancies, including the highly lethal pancreatic ductal adenocarcinomas. Here, we developed and tested a novel αvβ6-targeting peptide, DOTA-5G (1) radiolabeled with 68Ga, for PET/CT imaging and 177Lu for treatment. With the goal to develop a radiotheranostic, further modifications were made for increased circulation time, renal recycling, and tumor uptake, yielding DOTA-albumin-binding moiety-5G (2). Methods: Peptides 1 and 2 were synthesized on solid phase, and their affinity for αvβ6 was assessed by enzyme-linked immunosorbent assay. The peptides were radiolabeled with 68Ga and 177Lu. In vitro cell binding, internalization, and efflux of 68Ga-1 and 177Lu-2 were evaluated in αvβ6-positive BxPC-3 human pancreatic cancer cells. PET/CT imaging of 68Ga-1 and 68Ga-2 was performed on female nu/nu mice bearing subcutaneous BxPC-3 tumors. Biodistribution was performed for 68Ga-1 (1 and 2 h after injection), 68Ga-2 (2 and 4 h after injection), and 177Lu-1 and 177Lu-2 (1, 24, 48, and 72 h after injection). The 177Lu-2 biodistribution data were extrapolated for human dosimetry data estimates using OLINDA/EXM 1.1. Therapeutic efficacy of 177Lu-2 was evaluated in mice bearing BxPC-3 tumors. Results: Peptides 1 and 2 demonstrated high affinity (<55 nM) for αvβ6 by enzyme-linked immunosorbent assay. 68Ga-1, 68Ga-2, 177Lu-1, and 177Lu-2 were synthesized in high radiochemical purity. Rapid in vitro binding and internalization of 68Ga-1 and 177Lu-2 were observed in BxPC-3 cells. PET/CT imaging and biodistribution studies demonstrated uptake in BxPC-3 tumors. Introduction of the albumin-binding moiety in 177Lu-2 resulted in a 5-fold increase in tumor uptake and retention over time. Based on the extended dosimetry data, the dose-limiting organ for 177Lu-2 is the kidney. Treatment with 177Lu-2 prolonged median survival by 1.5- to 2-fold versus controls. Conclusion: 68Ga-1 and 177Lu-2 demonstrated high affinity for the integrin αvβ6 both in vitro and in vivo, were rapidly internalized into BxPC-3 cells, and were stable in mouse and human serum. Both radiotracers showed favorable pharmacokinetics in preclinical studies, with predominantly renal excretion and good tumor-to-normal-tissue ratios. Favorable human dosimetry data suggest the potential of 177Lu-2 as a treatment for pancreatic ductal adenocarcinoma.
引用
- Ganguly T, Bauer N, Davis RA, et al. Preclinical Evaluation of 68Ga- and 177Lu-Labeled Integrin αvβ6-Targeting Radiotheranostic Peptides. J Nucl Med. 2022. PMID: 36207137. doi:10.2967/jnumed.122.264749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。